Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology
-
HSBC Bank Plc - Form 8.5 (EPT/RI) - Wood Group (John) plc
-
Ice Fish Farm – Proposed change of company name
-
Duluth Holdings Inc. Announces First Quarter 2024 Financial Results
-
Publication of a Company Description
-
Man Group PLC : Form 8.3 - Barratt Developments plc
-
Early Signals by WOO X: Gigachad, Foxy, and Bitcoin Wizards are rising while ETH awaits a decisive breakthrough above $3,800
-
Dimensional Fund Advisors Ltd. : Form 8.3 - INTERNATIONAL PAPER CO - Ordinary Shares
-
TDOC INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Teladoc Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
-
Irdeto Wins for Anti-Piracy at the 2024 Cybersecurity Excellence Awards
-
Irdeto Wins for Anti-Piracy at the 2024 Cybersecurity Excellence Awards
-
Dimensional Fund Advisors Ltd. : Form 8.3 - TYMAN PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - BARRATT DEVELOPMENTS PLC - Ordinary Shares
-
Prosafe SE: Prosafe issued Conditional Letter of Intent for Safe Boreas
-
Blaze Pizza Announces Most Significant Menu Revamp in its History
-
Canada is undergoing a fragmented clean energy transition with radically different levels of provincial effort: report
-
Hywin Holdings Announces Receipt of Notification from Nasdaq
-
Fortuna publishes its 2023 Sustainability Report
-
Point and Atalaya Capital Management Close Oversubscribed $141 Million Home Equity Investment Rated Securitization
-
Fraser Institute News Release: Private clinics helped Saskatchewan reduce median medical wait times by nearly 50%
-
Intetics Inc. Recognized Across Multiple Sub-Lists in IAOP's 2024 Global Outsourcing 100
-
Intetics Inc. Recognized Across Multiple Sub-Lists in IAOP's 2024 Global Outsourcing 100
-
Net Asset Value(s)
-
Resolutions adopted by the Annual General Meeting of Shareholders of AS Tallinna Vesi 30.05.2024
-
Result of the auction of treasury bills on 30 May 2024
-
Metasphere Labs Appoints Dustin Muscato as Advisor for Carbon Credit Protocol Initiative
-
Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
-
Delphos Advises MPC Energy Solutions on a USD 34 million Non-Recourse Project Financing for the Construction of a 66MWp Solar PV plant in Guatemala
-
Fortude and Accure join forces to enhance Infor M3 and CloudSuite experience for Europe
-
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
-
Share Buyback Transaction Details May 23 – May 29, 2024
-
Form 8.5 (EPT/RI) - musicMagpie Plc
-
Form 8.5 (EPT/RI) - Trinity Exploration & Production Plc
-
Form 8.5 (EPT/RI) - Touchstone Exploration Inc
-
Form 8.5 (EPT/RI) - NewRiver REIT Plc
-
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
-
New prices for natural gas transmission services have been approved
-
Persistent Systems Selects Zscaler to Launch Technology Modernization and Renewable Energy Initiatives
-
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
-
Changes in organisational structure and management team of Telia Lietuva
-
Green Bioactives Reports Remarkable Cognitive Benefits of its Newly Launched Memory-boosting Nutraceutical Product, GBL-Memory¹
-
Interim financial report for 1 January - 31 March 2024 for FirstFarms A/S
-
Green Bioactives Reports Remarkable Cognitive Benefits of its Newly Launched Memory-boosting Nutraceutical Product, GBL-Memory¹
-
VINCI wins new works contract for Melbourne Airport in Australia
-
Form 8.5 (EPT/RI) - Renalytix plc
-
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
-
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
-
Samsung Bioepis to Present Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024
-
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
-
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel

